Linwei Lu
Impact in
- Biomaterials top 2%
- Nanoparticle-Based Drug Delivery
- Pharmaceutical Science top 5%
- Advanced Drug Delivery Systems
Papers in
-
- RNA Interference and Gene Delivery 12
- Advanced biosensing and bioanalysis techniques 4
- Biomaterials 16
- Nanoparticle-Based Drug Delivery 16
- Co-authors
- Weiyue Lu (24 shared papers)Changyou Zhan (9 shared papers)Zhilan Chai (9 shared papers)Cao Xie (15 shared papers)Jingcheng Dong (16 shared papers)Zhengxiao Zhao (13 shared papers)Huitong Ruan (5 shared papers)Danni Ran (5 shared papers)
- Journals
- Journal of Controlled Release (10 papers)Acta Pharmaceutica Sinica B (3 papers)International Immunopharmacology (2 papers)Molecular Pharmaceutics (2 papers)Pharmaceutics (1 paper)
- Partner nations
- ChinaSouth KoreaUnited States
In The Last Decade
Linwei Lu
41 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 106
- Biomaterials 544
- Pharmaceutical Science 90
- Biological Psychiatry 33
- Biomedical Engineering 514
- Molecular Biology 701
Countries citing papers authored by Linwei Lu
This map shows the geographic impact of Linwei Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linwei Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linwei Lu more than expected).
Fields of papers citing papers by Linwei Lu
This network shows the impact of papers produced by Linwei Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linwei Lu. The network helps show where Linwei Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Linwei Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 311 | |
| 2 | 2017 | 217 | |
| 3 | 2016 | 96 | |
| 4 | 2016 | 57 | |
| 5 | 2019 | 52 | |
| 6 | 2015 | 52 | |
| 7 | 2018 | 49 | |
| 8 | 2021 | 48 | |
| 9 | 2019 | 44 | |
| 10 | 2019 | 44 | |
| 11 | 2020 | 43 | |
| 12 | 2019 | 41 | |
| 13 | 2022 | 40 | |
| 14 | 2019 | 37 | |
| 15 | 2022 | 35 | |
| 16 | 2020 | 32 | |
| 17 | 2022 | 27 | |
| 18 | 2019 | 26 | |
| 19 | 2024 | 26 | |
| 20 | 2018 | 26 |
About Linwei Lu
Linwei Lu is a scholar working on Molecular Biology, Biomaterials, Biomedical Engineering, Immunology and Pharmacology, having authored 42 papers that have together received 1.5k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (16 papers), RNA Interference and Gene Delivery (12 papers), Nanoplatforms for cancer theranostics (9 papers), Flavonoids in Medical Research (6 papers), Immunotherapy and Immune Responses (4 papers), Traditional Chinese Medicine Studies (4 papers), Advanced biosensing and bioanalysis techniques (4 papers) and Advanced Glycation End Products research (3 papers). The work is most often cited by research in Biomaterials (544 citations), Pharmaceutical Science (90 citations), Biological Psychiatry (33 citations), Biomedical Engineering (514 citations) and Molecular Biology (701 citations). Linwei Lu has collaborated with scholars based in China, South Korea and United States. Frequent co-authors include Weiyue Lu, Changyou Zhan, Zhilan Chai, Cao Xie, Jingcheng Dong, Zhengxiao Zhao, Huitong Ruan, Danni Ran, Jianfen Zhou and Kuan Jiang. Their work appears in journals such as Journal of Controlled Release, Acta Pharmaceutica Sinica B, International Immunopharmacology, Molecular Pharmaceutics and Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.